Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03527108 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Apr 2026 to Dec 2026v18
  2. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 39 to confirmed 36
    • Site details revised at 2 of 2 sites
    v17
  3. Primary completion date: Apr 2025 to Apr 2026
    • Study completion date: Apr 2026 to Apr 2027
    v16
  4. Primary completion date: Apr 2024 to Apr 2025
    • Study completion date: Apr 2025 to Apr 2026
    v15
  5. Study sites: 1 to 2v14
Show 12 earlier versionsHide 12 earlier versions
  1. Primary completion date: Apr 2023 to Apr 2024
    • Study completion date: Apr 2024 to Apr 2025
    v13
  2. Re-verified, no change to tracked fieldsv12
  3. Trial status: Not Yet Recruiting to Recruitingv11 Show 4 more changesShow less
    • Primary completion date: Apr 1, 2023 to Apr 2023
    • Study completion date: Apr 1, 2024 to Apr 2024
    • Start date changed from estimate of Mar 2021 to Oct 8, 2020
    • Site details revised
  4. Start date: Sep 1, 2020 to Mar 2021v10
  5. Start date: Aug 1, 2020 to Sep 1, 2020v9 Show 5 more changesShow less
    • Primary endpoints: 2 to 1
    • Eligibility criteria expanded, about 78 words
    • Secondary endpoints: 10 to 4
    • Study description expanded, about 54 words
    • Site contact updated
  6. Enrollment target: 117 to 39
    • Interventions: Nivolumab (Drug), Nivolumab, ramucirumab (Drug) to Nivolumab (Drug), Ramucirumab (Drug)
    • Study description expanded, about 138 words
    • Study arms: 2 to 1
    v8
  7. Start date: Jun 1, 2020 to Aug 1, 2020v7
  8. Start date: Apr 1, 2020 to Jun 1, 2020v6
  9. Start date: Dec 1, 2019 to Apr 1, 2020v5
  10. Primary completion date: Apr 1, 2020 to Apr 1, 2023
    • Start date: Dec 1, 2018 to Dec 1, 2019
    • Study completion date: Apr 1, 2023 to Apr 1, 2024
    v4
  11. Start date: Jul 1, 2018 to Dec 1, 2018v3
  12. Primary endpoints revised (2)
    • Secondary endpoints revised (10)
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study will enroll patients with prior IO therapy (alone or in combination with chemotherapy or in combination with other IO agents) regardless of the PD-L1 level, into a non-randomized combination trial, with primary endpoint of disease control rate.
Trial Details
NCT Number NCT03527108
Lead Sponsor Fox Chase Cancer Center
Collaborators: Bristol-Myers Squibb, Eli Lilly and Company
Conditions
(from sponsor)		 Non Small Cell Lung Cancer
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov